N-(3-bromopropyl)-3,5-dichlorobenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-bromopropyl)-3,5-dichlorobenzamide
• 化学式: C₁₀H₁₀BrCl₂NO
• 分子量: 311.005
• InChiKey: KAAUWQVNYJIGEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-bromopropyl)-3,5-dichlorobenzamide 、 1-(pyridin-2-yl)-piperazine hydrochloride 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 以50%的产率得到3,5-dichloro-N-(3-(4-(pyridin-2-yl)piperazin-1-yl)propyl)benzamide
  参考文献：
  名称：

  Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors

  摘要：

  Rational drug design method has been used to generate 4-arylpiperazine carboxamides in an effort to develop safer, more potent and effective monoamine neurotransmitters reuptake inhibitors. Out of twenty-seven synthesized compounds, compound 9 displayed potent monoamine neurotransmitter reuptake inhibitory activity against HEK cells transfected with hSERT or hNET. A Surflex-Dock docking model of 9 was also studied.

  DOI：

  10.1016/j.bmc.2018.06.043
• 作为产物：
  描述：

  3,5-二氯苯甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(3-bromopropyl)-3,5-dichlorobenzamide
  参考文献：
  名称：

  신규한 카복사마이드 유도체 염 및 그 용도

  摘要：

  This invention relates to a novel carbazomide derivative salt having therapeutic effects for mental disorders, and its use. The compound of chemical formula 1 or a pharmaceutically acceptable salt thereof can treat or prevent mental disorders such as depression, anxiety disorders, panic disorders, obsessive-compulsive disorders, phobias, and attention deficit hyperactivity disorder. It can increase compliance, have minimal side effects, and have a therapeutic effect for mental disorders by effectively inhibiting the reuptake of serotonin, norepinephrine, or dopamine.

  公开号：

  KR101784964B1

文献信息

• 신규한 카복사마이드 유도체 염 및 그 용도
  申请人：INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY 전남대학교산학협력단(220040365775) BRN ▼409-82-11942

  公开号：KR101784964B1

  公开（公告）日：2017-10-12

  본 발명은 정신장애 치료 효과를 갖는 신규한 카복사마이드 유도체 염 및 그 용도에 관한 것으로, 상기 화학식 1의 화합물 또는 이의 약학적으로 허용 가능한 염으로써, 우울증, 불안장애, 공황장애, 강박장애, 공포증 및 주의력결핍 과다행동장애 등의 정신장애를 치료 또는 예방할 수 있으며, 관해율을 높일 수 있고, 부작용이 적으며, 세로토닌, 노르에피네프린 또는 도파민의 재흡수를 효과적으로 억제할 수 있는 정신장애 치료 효과를 갖는 신규한 카복사마이드 유도체 염 및 그 용도에 관한 것이다.

  This invention relates to a novel carbazomide derivative salt having therapeutic effects for mental disorders, and its use. The compound of chemical formula 1 or a pharmaceutically acceptable salt thereof can treat or prevent mental disorders such as depression, anxiety disorders, panic disorders, obsessive-compulsive disorders, phobias, and attention deficit hyperactivity disorder. It can increase compliance, have minimal side effects, and have a therapeutic effect for mental disorders by effectively inhibiting the reuptake of serotonin, norepinephrine, or dopamine.
• Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors
  作者：Suresh Paudel、Yongkai Cao、Shuohan Guo、Byeongkwan An、Kyeong-Man Kim、Seung Hoon Cheon

  DOI：10.1016/j.bmc.2015.08.022

  日期：2015.10

  A series of 4-benzylpiperidine carboxamides were designed and synthesized, and tested for their dual (serotonin and norepinephrine) reuptake inhibition. The synthesis of 4-benzylpiperidine carboxamides involved two main steps: amidation and substitution. Derivatives with 3 carbon linker displayed better activity than with 2 carbon linker. 4-Biphenyl- and 2-naphthyl-substituted derivatives 7e and 7j showed greater dual reuptake inhibition than standard drug venlafaxine HCl. (C) 2015 Elsevier Ltd. All rights reserved.
• Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors
  作者：Suresh Paudel、Ningning Sun、Daulat Bikram Khadka、Goon Yoon、Kyeong-Man Kim、Seung Hoon Cheon

  DOI：10.1016/j.bmc.2018.06.043

  日期：2018.8

  Rational drug design method has been used to generate 4-arylpiperazine carboxamides in an effort to develop safer, more potent and effective monoamine neurotransmitters reuptake inhibitors. Out of twenty-seven synthesized compounds, compound 9 displayed potent monoamine neurotransmitter reuptake inhibitory activity against HEK cells transfected with hSERT or hNET. A Surflex-Dock docking model of 9 was also studied.